Definium's Psychedelic-Derived Pill Clears Key Hurdle in Depression, Sending Stock Surging 47%

A San Francisco-based company said Monday that its experimental once-dose antidepressant, derived from lysergide — a psychedelic compound — produced a statistically significant and clinically meaningful reduction in depression symptoms compared with placebo in a large Phase 3 trial, igniting a 47% surge in its shares and renewed debate about whether psychedelic-derived medicines could one day enter mainstream psychiatry.

Definium Therapeutics (Nasdaq: DFTX) disclosed the results from its Phase 3 “Emerge” trial in an 8-K filing with the Securities and Exchange Commission on June 22. The study measured change in total score on the Montgomery-Åsberg Depression Rating Scale (MADRS), a clinician-administered instrument widely used as a primary endpoint in antidepressant trials. Patients who received a single oral disintegrating tablet of DT120 showed a MADRS total score that was 8.1 points lower than placebo at Week 6 (p<0.0001).

MADRS is a validated clinician-administered rating scale — not a patient-reported outcome — widely accepted by regulators as a primary endpoint for antidepressant trials, though it measures symptom severity rather than hard clinical endpoints such as hospitalization or mortality, a distinction regulators and payers weigh carefully.

The safety readout was notable. The company reported that 99% of treatment-emergent adverse events were rated mild to moderate in severity, and the trial detected no signal of suicidality — a concern that has historically accompanied fast-acting agents in this class.

If the finding is confirmed in a second Phase 3 trial, DT120 would be the first oral psychedelic-class antidepressant to reach the market. The FDA has not reviewed or approved the drug; a new drug application would require at minimum a second adequate and well-controlled pivotal study, and the agency’s review timeline remains unknown.

The clinical stakes are substantial. Major depressive disorder is among the most prevalent disabling conditions worldwide, affecting tens of millions of Americans, and treatment-resistant depression — a subgroup for whom multiple standard therapies have failed — represents a major unmet need with few approved options. No psychedelic-derived compound has previously succeeded in a Phase 3 trial for major depressive disorder broadly defined. Compass Pathways’ COMP360 (synthetic psilocybin) met its primary endpoint in two Phase 3 trials earlier in 2025–2026, but those trials were specifically in treatment-resistant depression — a distinct, more severely ill subpopulation defined by failure of prior therapies — not in the broader MDD population enrolled in Emerge.

Definium’s shares closed approximately 47% above the prior day’s close on the day of the announcement. Investors should note that a single positive Phase 3 trial does not guarantee regulatory approval, commercial launch, or any particular return — and that a second Phase 3, the full FDA review, and manufacturing scale-up all represent material hurdles between Monday’s topline read and any eventual prescription.

Definium has not disclosed a timeline for initiating a confirmatory study or engaging in a pre-NDA meeting with the FDA.

Correction — June 23, 2026: Three errors have been corrected in this article. (1) The Montgomery-Åsberg Depression Rating Scale (MADRS) was originally described as “a surrogate, patient-reported outcome measure.” MADRS is a clinician-administered rating scale, not patient-reported; this description has been corrected. (2) The DFTX end-of-day stock gain was originally stated as “approximately 53%”; trading data shows the stock closed approximately 47% above its prior close on the day of the announcement, and the figure has been corrected throughout. (3) The original text stated that “no psychedelic-derived compound has previously succeeded in a Phase 3 trial in MDD” without noting that Compass Pathways’ COMP360 psilocybin met its primary endpoint in two Phase 3 trials for treatment-resistant depression before this announcement; a clarifying sentence distinguishing TRD from the broader MDD population enrolled in Emerge has been added.